DOJ Criminal Prosecutions of Peptide Distributors (2024-2025) — VialBase News
DOJ Criminal Prosecutions of Peptide Distributors
Summary
Between 2024 and 2025, the Department of Justice escalated peptide enforcement from civil actions to criminal prosecutions. Three cases established critical legal precedents: Tailor Made Compounding (guilty plea, $1.79M forfeiture), All American Peptide (guilty plea, misbranded drugs), and BioPeptide Labs (indictment for conspiracy and fraud). These cases collectively demolished the “research chemical” defense and established that the DOJ will pursue felony charges against peptide distributors.
Background
Tailor Made Compounding (TMC)
The landmark case. Tailor Made Compounding LLC, operated by Jeremy Delk, pleaded guilty to one felony count of distributing unapproved new drugs.
Substances involved: BPC-157, CJC-1295, Ipamorelin, LGD-4033
Sentence and penalties:
- Company: $1,788,906.82 forfeiture
- Jeremy Delk: 3 years probation, 4 months home incarceration, $20,000 fine
- Delk permanently barred from prescription drug distribution
Aggravating factors:
- Delk attempted to hide records from FDA inspectors during a 2018 inspection
- TMC issued a sterility recall in 2022
- Connections to a horse racing doping ring emerged during investigation
All American Peptide
The Kovaleskis owned and operated All American Peptide, which from 2014 to January 2019 marketed and distributed substances primarily used by bodybuilders through its website.
Substances involved: Tadalafil (prescription drug), SARMs, various peptides, other unapproved drugs
Charges: Guilty plea to selling misbranded and unapproved new drugs. The operation generated approximately $3 million in revenue.
Key legal point: The DOJ prosecution demonstrated that selling “research chemicals” that are actually prescription drugs (like tadalafil) or unapproved drugs eliminates any research-use defense.
BioPeptide Labs
Charged with conspiracy to commit wire fraud and distribute misbranded drugs.
Key details:
- Indictment revealed deceptive marketing practices
- Products were sold as “for research purposes” but marketed to human users
- The conspiracy charge (vs. simple distribution) indicates DOJ is pursuing more serious theories of liability
Impact
- Criminal precedent established: The Tailor Made case proved the DOJ will pursue felony charges, not just civil penalties
- “Research chemical” defense destroyed: The Intended Use Doctrine — examining actual marketing, customer base, and business practices rather than label disclaimers — is now established prosecution doctrine
- Personal liability: Owner Jeremy Delk received personal criminal penalties, demonstrating that corporate structure does not shield individuals
- Financial consequences: $1.79M forfeiture shows the government will seize profits
- Escalation pattern: Warning letters to civil action to criminal prosecution — the enforcement ladder is now fully established
- Broader industry effect: Multiple vendors shut down preemptively after these prosecutions became public
What This Means for Researchers
- Federal criminal prosecution is now a demonstrated risk for peptide vendors who market to humans
- The “research use only” disclaimer is legally meaningless if other evidence suggests human use intent
- Customers face potential exposure: purchase records seized in criminal investigations could identify buyers
- The DOJ’s willingness to pursue conspiracy charges means that business partners, suppliers, and even marketing contractors could face liability
- These cases are being used as templates for future prosecutions — the DOJ has a proven playbook